Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | CA12 | O43570 | 3/20 | 0.55 |
| ▸ | CA1 | P00915 | 3/20 | 0.55 |
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | CA9 | Q16790 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25529330 | 0.86 | MEN1 (0.61) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL891881 | 0.85 | MEN1 (0.69) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL7876576 | 0.85 | MEN1 (0.69) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL15788844 | 0.83 | KMT2A (0.72) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL26911797 | 0.82 | MEN1 (0.66) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL18737910 | 0.81 | MEN1 (0.64) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL5355079 | 0.81 | MEN1 (0.64) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL892401 | 0.81 | MEN1 (0.77) | MEN1PABPC1KMT2ACA12CA1 | |
| Hydrochloric Acid SCHEMBL1335355 | 0.80 | MEN1 (0.75) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL5353245 | 0.80 | MEN1 (0.75) | MEN1PABPC1KMT2ACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303577-A1 | TEMOZOLOMIDE ANALOGS AND METHODS OF USE | ST. JOHN'S CANCER INSTITUTE (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303577-A1 | TEMOZOLOMIDE ANALOGS AND METHODS OF USE | ST. JOHN'S CANCER INSTITUTE (US) | 2023-09-28 | — | — | US | disclosed |
| WO-2022026756-A1 | TEMOZOLOMIDE ANALOGS AND METHODS OF USE | ST. JOHN'S CANCER INSTITUTE (US) | 2022-02-03 | — | — | WO | disclosed |
| US-11014953-B2 | Trigger-activatable metabolic sugar precursors for cancer-selective labeling and targeting | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2021-05-25 | — | — | US | disclosed |
| US-8258294-B2 | Process for the preparation of temozolomide and analogs | CIPLA LIMITED (IN) | 2012-09-04 | — | — | US | disclosed |
| US-8232392-B2 | Process for preparing temozolomide | CHEMI S.P.A. (IT) | 2012-07-31 | — | — | US | disclosed |
| US-8232392-B2 | Process for preparing temozolomide | CHEMI S.P.A. (IT) | 2012-07-31 | — | — | US | disclosed |
| US-7737284-B2 | Synthesis of temozolomide and analogs | SCHERING PLOUGH CORP. (US) | 2010-06-15 | — | — | US | disclosed |
| US-20100036121-A1 | Process for preparing temozolomide | CHEMI S.P.A. (IT) | 2010-02-11 | — | — | US | disclosed |
| US-20100036121-A1 | Process for preparing temozolomide | CHEMI S.P.A. (IT) | 2010-02-11 | — | — | US | disclosed |
| EP-2151442-A2 | Process for preparing temozolomide | Chemi SPA (IT) | 2010-02-10 | — | — | EP | disclosed |
| US-20090326028-A1 | Process for the preparation of temozolomide and analogs | CIPLA LIMITED (IN) | 2009-12-31 | — | — | US | disclosed |
| US-7612202-B2 | Process for preparing temozolomide | CHEMAGIS, LTD. (IL) | 2009-11-03 | — | — | US | disclosed |
| US-20090023919-A1 | SYNTHESIS OF TEMOZOLOMIDE AND ANALOGS | SCHERING CORPORATION | 2009-01-22 | — | — | US | disclosed |
| US-7446209-B2 | Diazotizing a blocked 5-amino-1H-imidazole-4-carboxamide; hydrolysis; antitumor agents | SCHERING CORPORATION (US) | 2008-11-04 | — | — | US | disclosed |
| US-7173021-B2 | Synthesis of temozolomide esters as potent anticancer pro-drugs for topical and transdermal applications in treatments of cancers | TIANJIN NORTH PHARM SCI-TECH CO., LTD. (CN) | 2007-02-06 | — | — | US | disclosed |
| US-20060047117-A1 | Synthesis of temozolomide esters as potent anticancer pro-drugs for topical and transdermal applications in treatments of cancers | TIANJIN NORTH PHARM SCI-TECH CO., LTD. (CN) | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11014953-B2 | Trigger-activatable metabolic sugar precursors for cancer-selective labeling and targeting | GPI, SLC2A1, SLC2A4 | MEN1 2008/4885PABPC1 2384/4885KMT2A 1397/4885 |
| US-20060047117-A1 | Synthesis of temozolomide esters as potent anticancer pro-drugs for topical and transdermal applications in treatments of cancers | TET1, SLC16A1, ADH1A | MEN1 222/4885PABPC1 4434/4885KMT2A 1472/4885 |
| US-20090326028-A1 | Process for the preparation of temozolomide and analogs | IDH3A, IDH3B, IDH2 | MEN1 81/4885PABPC1 4306/4885KMT2A 683/4885 |
| US-20090023919-A1 | SYNTHESIS OF TEMOZOLOMIDE AND ANALOGS | MGMT, TYMS, MCL1 | MEN1 42/4885PABPC1 2492/4885KMT2A 334/4885 |
| US-20100036121-A1 | Process for preparing temozolomide | MGMT, NNMT, NOS2 | MEN1 910/4885PABPC1 3423/4885KMT2A 248/4885 |
| US-20230303577-A1 | TEMOZOLOMIDE ANALOGS AND METHODS OF USE | MGMT, TOP2B, IDH3B | MEN1 882/4885PABPC1 2801/4885KMT2A 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.